Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults
The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [ 3 , 5 , 6 , 20 , 22 , 35 ]. We designed a neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous his...
Gespeichert in:
Veröffentlicht in: | Clinical orthopaedics and related research 2008-06, Vol.466 (6), p.1292-1301 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [
3
,
5
,
6
,
20
,
22
,
35
]. We designed a neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous histiocytoma of bone in an attempt to improve survival. We report the results of treating 53 adults (age 18–77 years) diagnosed with nonmetastatic extremity osteosarcoma or malignant fibrous histiocytoma. Preoperative chemotherapy consisted of intravenous doxorubicin followed by intraarterial cisplatinum administered repetitively every 3 weeks for three to five cycles, depending on tumor response assessed by serial arteriography. Dose and duration of cisplatin were adjusted for tumor size. After resection, good responders (90% or greater necrosis) underwent treatment with the same agents and poor responders were treated with alternative agents for longer duration. Minimum followup was 24 months (mean, 111 months; range, 24–235 months). Estimated Kaplan-Meier survival at 10 years was 82% and event-free survival was 79%. Forty-one patients (77%) had a good histologic response and 92% (49 of 53) underwent limb-sparing procedures. Local recurrence occurred in two patients (4%). These results compared favorably with those reported in the current literature.
Level of Evidence:
Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence. |
---|---|
ISSN: | 0009-921X 1528-1132 |
DOI: | 10.1007/s11999-008-0252-1 |